Effect of Imrecoxib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects
试验速览
- 阶段
- 1 期
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Pharmacokinetics parameters like Cmax、tmax and AUC0-t of Warfarin
研究概览
简要总结
The objective of this study was to determine the effects of Imrecoxib, an anti-infiammatory/analgesic agent that primarily inhibits COX-2 and not COX-1 at therapeutic doses, on the steady-state pharmacokinetic profile and hypoprothrombinemic effect of warfarin in healthy volunteers.
详细描述
This is a single center open label study to assess the effect of Imrecoxib on the PK of Warfarin in Healthy Volunteers. The goals of this study are as follows: assess the PK of warfarin when administered alone ,and with Imrecoxib ; assess INR of warfarin when administered alone, and with Imrecoxib; to assess the effect of Imrecoxib on the PK/PD of warfarin, to assess the safety and tolerability of warfarin administered with Imrecoxib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Adult males aged 18 to 40 years,with BMI 19~
- •Subjects who, in the opinion of the investigator, are healthy as determined by medical history, physical examination, and 12 Lead ECG.
- •Willing and able to provide written informed consent.
排除标准
- •History of hypersensitivity to Imrecoxib and its components.
- •History or current clinically important systemic illnesses, including but not limited to cardiovascular, pulmonary, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological, neurological, or psychiatric diseases, or any conditions that may place the subject at increased risk as determined by the investigator.
- •Any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- •History of alcohol dependent, habitual heavy users of caffeinated beverages judged by the investigator.
- •Have had significant blood loss (>200mL) or have donated 1 or more units of blood or plasma within 12 weeks prior to study entry.
- •Have a positive test at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb).
- •Have used any drugs or substances (including herbal supplements) known to inhibit or induce cytochrome (CYP) P450enzymesincluding CYP3A4, CYP2C8 and CYP2C9 within 4 weeks prior to the first dose and throughout the study.
研究组 & 干预措施
Imrecoxib&Warfarin
干预措施: Warfarin (Drug)
Imrecoxib&Warfarin
干预措施: Imrecoxib (Drug)
结局指标
主要结局
Pharmacokinetics parameters like Cmax、tmax and AUC0-t of Warfarin
时间窗: Predose up to 144 hours post Day 1 and Day 10 dose
次要结局
- Prothrombintime after Warfarin dosing(6 hours to 144 hours post Day 1 and Day10 dose)